Triarii Capital Management LP lowered its stake in shares of Shire PLC (NASDAQ:SHPG) by 10.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 40,500 shares of the biopharmaceutical company’s stock after selling 4,500 shares during the quarter. Shire comprises 7.5% of Triarii Capital Management LP’s portfolio, making the stock its 4th largest holding. Triarii Capital Management LP’s holdings in Shire were worth $7,341,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors also recently made changes to their positions in the business. Cornerstone Wealth Management LLC purchased a new position in shares of Shire during the second quarter worth $145,000. CIBC Private Wealth Group LLC raised its position in Shire by 22.6% in the second quarter. CIBC Private Wealth Group LLC now owns 43,358 shares of the biopharmaceutical company’s stock worth $7,319,000 after acquiring an additional 8,005 shares in the last quarter. Linscomb & Williams Inc. bought a new stake in Shire in the second quarter worth about $210,000. Greenleaf Trust raised its position in Shire by 32.0% in the second quarter. Greenleaf Trust now owns 3,194 shares of the biopharmaceutical company’s stock worth $539,000 after acquiring an additional 774 shares in the last quarter. Finally, SG Americas Securities LLC raised its position in Shire by 1,634.4% in the second quarter. SG Americas Securities LLC now owns 193,547 shares of the biopharmaceutical company’s stock worth $32,671,000 after acquiring an additional 182,388 shares in the last quarter. 20.49% of the stock is owned by hedge funds and other institutional investors.
A number of brokerages have issued reports on SHPG. Royal Bank of Canada set a $195.00 target price on Shire and gave the stock a “buy” rating in a research report on Tuesday, October 23rd. BidaskClub downgraded Shire from a “buy” rating to a “hold” rating in a research note on Friday, November 30th. Zacks Investment Research reissued a “hold” rating on shares of Shire in a research note on Thursday, November 15th. Berenberg Bank downgraded Shire from a “buy” rating to a “hold” rating in a research note on Friday, September 7th. Finally, ValuEngine raised Shire from a “sell” rating to a “hold” rating in a research note on Friday, August 24th. Nine investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $201.11.
NASDAQ SHPG traded down $3.72 on Friday, hitting $174.41. 34,142 shares of the stock traded hands, compared to its average volume of 1,525,159. Shire PLC has a 12 month low of $123.73 and a 12 month high of $182.47. The firm has a market cap of $52.13 billion, a price-to-earnings ratio of 11.49, a price-to-earnings-growth ratio of 1.54 and a beta of 1.01. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 0.36.
Shire (NASDAQ:SHPG) last posted its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported $3.64 EPS for the quarter, missing the Zacks’ consensus estimate of $3.65 by ($0.01). The company had revenue of $3.87 billion during the quarter. Shire had a return on equity of 12.70% and a net margin of 30.63%. Shire’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same period in the prior year, the firm earned $3.81 earnings per share. Analysts forecast that Shire PLC will post 15.09 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Shire PLC (SHPG) Holdings Cut by Triarii Capital Management LP” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.dispatchtribunal.com/2018/12/07/shire-plc-shpg-holdings-cut-by-triarii-capital-management-lp.html.
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Read More: Dividend Stocks – Are They Right For You?
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.